Hansoh Pharma licenses cancer drug Aumolertinib to Glenmark for global territories

On December 16, 2025, Hansoh Pharmaceutical Group's subsidiary, Jiangsu Hansoh Pharmaceutical Group Co. Ltd., entered an exclusive license agreement with Glenmark Specialty S.A. for Aumolertinib. This agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib, a third-generation EGFR-TKI for non-small cell lung cancer (NSCLC), across territories including the Middle East, Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS, and certain Caribbean countries.

Under the terms, Hansoh will receive an upfront payment, with potential regulatory and commercial milestone payments possibly exceeding $1 billion. Additionally, Hansoh will earn tiered royalties on net sales generated in the licensed territories.

Aumolertinib is China's first original third-generation EGFR-TKI innovative drug, with four approved indications in China since March 2020. Most recently, in June 2025, it was approved by the MHRA in the United Kingdom for marketing under the trade name Aumseqa.